Rizoli Sandro
Department of Surgery & Critical Care Medicine, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
J Trauma. 2011 May;70(5 Suppl):S17-8. doi: 10.1097/TA.0b013e31821a4d89.
PlasmaLyte is a family of balanced crystalloid solutions with multiple different formulations available worldwide according to regional clinical practices and preferences. It closely mimics human plasma in its content of electrolytes, osmolality, and pH. These solutions also have additional buffer capacity and contain anions such as acetate, gluconate, and even lactate that are converted to bicarbonate, CO2, and water. The advantages of PlasmaLyte include volume and electrolyte deficit correction while addressing acidosis. It shares the same problems as most other crystalloid fluids (fluid overload, edema with weight gain, lung edema, and worsening of the intracranial pressure). A unique concern is that most formulations contain magnesium, which may affect peripheral vascular resistance, heart rate, and worsen organ ischemia. There are few studies on its use in trauma or hypovolemic shock. There is no evidence that PlasmaLyte is superior to other crystalloids for the prehospital management of traumatic hypovolemia.
聚明胶肽是一类平衡晶体溶液，根据不同地区的临床实践和偏好，在全球有多种不同的配方。它在电解质含量、渗透压和pH值方面与人体血浆非常相似。这些溶液还具有额外的缓冲能力，并含有醋酸根、葡萄糖酸根甚至乳酸根等阴离子，这些阴离子会转化为碳酸氢根、二氧化碳和水。聚明胶肽的优点包括在纠正酸中毒的同时纠正容量和电解质缺乏。它与大多数其他晶体液存在相同的问题（液体过载、体重增加导致水肿、肺水肿和颅内压升高）。一个独特的问题是，大多数配方都含有镁，这可能会影响外周血管阻力、心率，并加重器官缺血。关于其在创伤或低血容量性休克中的应用研究很少。没有证据表明聚明胶肽在院前创伤性低血容量管理方面优于其他晶体液。
